RxDoctor Payments Data

Brian Shelley, MD

Ophthalmology · Greenville, SCNPI 1346274453

Payments from drug & device makers

$5,151in general payments, 2019–2025

Across 64 payments — averaging $80.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopervision Inc.$3K
  • Alcon$1K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$146
  • Johnson & Johnson Surgical Vision, Inc.$124
  • Tarsus Pharmaceuticals, Inc.$109
  • NEW World Medical,inc.$105
  • plus $315 from 7 others

What the payments were for

  • Speaking & faculty fees$3,33365%
  • Food & beverage$1,79935%
  • Education$180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,151 in reported general payments places this provider in the 70th percentile of 293 ophthalmology providers in South Carolina.

See all ophthalmology providers in South Carolina

Medicare billing

Part B allowed, 2024
$442,534
Medicare patients
1,506
Services billed
3,367

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine57$66,390
LumiganBimatoprost42$27,433
XiidraLifitegrast16$25,071
Cyclosporine26$14,389
RocklatanNetarsudil Mesylat/Latanoprost16$5,992
Latanoprost548$5,290
Loteprednol Etabonate28$4,020
Prednisolone Acetate92$4,012
Brimonidine Tartrate34$3,999
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat91$2,215
Travoprost12$1,738
Timolol Maleate92$1,526
Ketorolac Tromethamine65$1,281
MoxifloxacinMoxifloxacin Hcl44$1,077
Tobramycin-DexamethasoneTobramycin/Dexamethasone13$475

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$72$93,82299 claims
Bausch & Lomb Americas Inc.Xiidra$43$25,07116 claims
Aerie Pharmaceuticals, Inc.Rocklatan$14$5,99216 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$146$4,02028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 293 ophthalmology providers in South Carolina.

Other ophthalmology in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →